United Homes Group stock plunges after Nikki Haley, directors resign
DUBLIN - Investment firm Citadel Group has disclosed a 1.28% stake in Mural Oncology plc, according to a regulatory filing published Friday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds 222,999 shares representing 1.28% of the biopharmaceutical company, alongside short positions equivalent to 1.17% of the company’s stock.
According to the filing, Citadel’s position includes 210,699 owned or controlled shares and 12,300 shares through stock-settled derivatives. The firm also maintains short positions of 203,600 shares through stock-settled derivatives.
The regulatory document details multiple transactions conducted on October 16, including purchases of Mural Oncology shares at prices ranging from $2.07 to $2.09 per share, alongside corresponding sales at similar price points.
The filing also reveals Citadel’s options positions, including purchased put options expiring in December 2025 and January 2027, as well as call options with various strike prices ranging from $2.50 to $7.50 with expiration dates extending to March 2026.
Irish takeover rules require disclosure of positions representing 1% or more of a company’s relevant securities. The information was submitted through a Form 8.3 filing, which is required for opening position disclosures under Irish Takeover Panel regulations.
Mural Oncology, listed on the Irish stock exchange with shares trading at approximately $2.07-$2.09 based on the reported transactions, focuses on oncology therapeutics development.
The disclosure was based on a regulatory filing statement submitted to the Irish Takeover Panel.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.